Cytosorbents Corporation CTSO
$5.96
$0.234.01%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.63M | 8.86M | 9.23M | 9.49M | 9.62M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.63M | 8.86M | 9.23M | 9.49M | 9.62M |
| Cost of Revenue | 2.58M | 2.73M | 2.43M | 2.82M | 2.80M |
| Gross Profit | 7.05M | 6.13M | 6.80M | 6.67M | 6.81M |
| SG&A Expenses | 7.96M | 8.15M | 9.61M | 8.41M | 9.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.00M | 11.91M | 13.29M | 12.15M | 13.23M |
| Operating Income | -2.37M | -3.04M | -4.05M | -2.66M | -3.62M |
| Income Before Tax | -4.42M | -5.13M | -5.50M | -3.57M | 1.95M |
| Income Tax Expenses | -- | -- | 0.00 | -401.00K | -- |
| Earnings from Continuing Operations | -4.42M | -5.13M | -5.50M | -3.17M | 1.95M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.42M | -5.13M | -5.50M | -3.17M | 1.95M |
| EBIT | -2.37M | -3.04M | -4.05M | -2.66M | -3.62M |
| EBITDA | -2.02M | -2.69M | -3.69M | -2.30M | -3.21M |
| EPS Basic | -1.41 | -1.64 | -1.75 | -1.01 | 0.62 |
| Normalized Basic EPS | -0.83 | -1.02 | -0.92 | -0.67 | 0.39 |
| EPS Diluted | -1.41 | -1.64 | -1.75 | -1.01 | 0.60 |
| Normalized Diluted EPS | -0.83 | -1.02 | -0.92 | -0.67 | 0.36 |
| Average Basic Shares Outstanding | 3.14M | 3.14M | 3.14M | 3.14M | 3.13M |
| Average Diluted Shares Outstanding | 3.14M | 3.14M | 3.14M | 3.14M | 3.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |